Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival Alain P. Gobert, David J. McGee, Mahmood.

Slides:



Advertisements
Similar presentations
The H pylori Story – Helicobacter pylori through the ages
Advertisements

Nursing Care of Patients WithUpper GI Disturbances
Role of H.pylori in Peptic Ulcer and drugs used in Treatment Dr. Abdulaziz al-Khattaf.
Antiulcer drugs.
Drugs Used For Peptic Ulcer
Peptic ulcer.
Helicobacter pylori Jayli Schmidt. History Discovered in 1982 by Barry Marshall and Robin Warren – They won the Nobel Prize in 2005 for this discovery.
Copyright (c) 2004 Elsevier Inc. All rights reserved. Drugs for Peptic Ulcer Disease Chapter 73.
An infectious bacterium: Helicobacter pylori Tony 10/07/2005.
D YSPEPSIA & P EPTIC U LCER By Dr. Zahoor 1. D YSPEPSIA What is Dyspepsia ?  Dyspepsia is used to describe number of upper abdominal symptoms such as.
DIGESTIVE DISEASES. Main Characteristics  The digestive system is composed of:
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Comparative evaluation of conventional methods and Elisa based IgG antibodies detection for diagnosis of helicobacter pylori infection in cases of dyspepsia.
Treatment of H Pylori -Peptic Ulcer Disease By Prof. Hanan Hagar Department of Physiology and Pharmacology.
Diagnostic Evaluation Radiographic barium study –Less sensitive in small ulcers
LECTURE-2 Stomach and Gastric Juice Function of gastric juice
Peptic Ulcer Disease. Peptic ulcer  refers to erosion of the mucosa lining any portion of the G.I. tract.  It is defined as : A circumscribed ulceration.
Stomach Ulcer(Peptic Ulcer) Stomach ulcer or peptic ulcer is the damage of the protective layer (lining) of stomach or gastrointestinal tract It may be.
Anti Ulceration and Anti Emetics Nur Irjawati S. Kawang, S.Si,
Helicobacter pylori Clinical Medicine.Medical department.Shandong University.
Gastric Acid Secretion 1. Acid synthesis – regulated by 3 transporters Lumen Plasma Parietal cell.
Pharmacology B Lin, I-Yao. A 43y/o male CEO of a multinational company experienced severe burning pain one and a half hour after a sumptuous lunch. This.
Clinical Microbiology (MLCM- 201) Prof. Dr. Ebtisam. F. El Ghazzawi. Medical Research Institute (MRI) Alexandria University.
Biology of Disease CH0576 Peptic Ulceration Role of H. pylori.
Helicobacter First one discovered in 1983 by Drs. Barry Marshall and J. Robin Warren Originally classified as a Campylobacter.
Sebastian Suerbaum & Christine Josenhans
D YSPEPSIA & P EPTIC U LCER By Dr. Zahoor 1. D YSPEPSIA What is Dyspepsia ?  Dyspepsia is used to describe number of upper abdominal symptoms such as.
Peptic Ulcer Disease Dr. Wael H. Mansy, MD Assistant Professor College of Pharmacy King Saud University.
Local pH elevation mediated by the intrabacterial urease of Helicobacter pylori cocultured with gastric cells J. Clin. Invest. 106:339–347 (2000).
Helicobacter Pylori By Torin Hester.
Role of H.pylori in Peptic Ulcer and drugs used in Treatment Dr. Abdulaziz al-Khattaf.
1 Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival PNAS November 20, 2001 vol. 98 no.
Helicobacter pylori Vaccine Development Catherine O. Johnson March 9, 2006.
Diagnosis of PUD.
GASTROINTESTINAL DISEASES By: Jenny Ruiz 10/13/09 – TR 7pm.
Role of H. pylori in Peptic Ulcer and drugs used in Treatment Dr. Fawzia Alotaibi.
Role of H.pylori in Peptic Ulcer and drugs used in Treatment Dr. Fawzia ALOtaibi.
Peptic Ulcer and Helicobacter pylori Infection. History: In 1983, Barry Marshall and Robin Warren, reported that H. pylori is associated with chronic.
“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.
CLINICAL INTEGRATION OCTOBER 27, 2009 PENAFLOR*QUINTO*RAMOS*SICAT* SUACO*TIO CUISON DIAGNOSTICS.
By: Ashley Whiteaker.  Peptic ulcers are ulcers that form in the stomach or the upper part of the small intestine, called the duodenum. It is an sore.
Helicobacter pylori and gastric ulcers. Helicobacter pylori (H. pylori) is a spiral shaped bacterium that lives on the lining of the stomach; inflammation.
R3 정명화 /Prof. 장재영 Gastrointest. Endosc. 2012; 75:39-46.
HELICOBACTER PYLORI Millions of years old microorganism of mankind Causes a spectrum of diseases Obviously requires high priority Treatment strategies.
ACID-PEPTIC DISEASE AND TREATMENT Introduction - A. Acid peptic includes: 1.Peptic ulcers (stomach and duodenal) 2.Gastroesophageal reflux disorders (GERD)
Helicobacter pylori and Gastric Lymphoma
Clinical Practice Helicobacter pylori Infection Kenneth E.L. McColl, M.D. N Engl J Med Volume 362(17): April 29, 2010.
Department: Microbiology
Fatimah Abdullah 6th year MS, KFU
Gastroesophageal Reflux Disease affecting the upper gastrointestinal tract. 10% of the population experience Heartburn is the cardinal symptom.
Role of H.pylori in Peptic Ulcer and drugs used in Treatment
Follow-up Testing After Treatment of Helicobacter Pylori Infections: Cautions, Caveats, and Recommendations  Taraq A. Attumi, MD, David Y. Graham, MD 
Gastritis.
Dyspepsia & Peptic Ulcer
Drugs in peptic ulcer (H2 blockers and proton pump inhibitors)
Role of H.pylori in Peptic Ulcer and drugs used in Treatment
LECTURE: Helicobacter Pylori
Gastrointestinal pathogens: Helicobacter pylori
Dyspepsia & Peptic Ulcer
Volume 148, Issue 4, Pages e3 (April 2015)
Peptic Ulcer.
GASTRITIS By : BILAL HUSSEIN.
Follow-up Testing After Treatment of Helicobacter Pylori Infections: Cautions, Caveats, and Recommendations  Taraq A. Attumi, MD, David Y. Graham, MD 
Volume 148, Issue 4, Pages e3 (April 2015)
gastrointestinal block
-جرثومة المعدة-.
Campylobacter Microbiology properties Curved (comma- or S-shaped)
Peptic Ulcer.
Presentation transcript:

Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival Alain P. Gobert, David J. McGee, Mahmood Akhtar, George L. Mendz, Jamie C. Newton, Yulan Cheng, Harry L. T. Mobley, and Keith T. Wilson Presented by Mihaela C. Badea-Mic

So, Who Am I? Gram negative bacteria inside the stomach and duodenum The Helicobacter Foundation

Who discovered me? 1983-Campylobacter pyloridis Tomb et al sequenced the HP genome The Helicobacter Foundation, 2005

Epidemiology Prevalence (USA) African-American Hispanic Eastern Europeans UBIQUITOUS 50% world population The Helicobacter Foundation, 2005

Pathophysiology The most common route of H. Pylori infection Oral to oral Fecal to oral PS: watch your pets!

Histology The Helicobacter Foundation, 2005

Diagnosis ・ Breath test - Based on the detection of the products of urea The Helicobacter Foundation, 2005

Diagnosis- cont. ・ Esophagogastroduodenoscopy with biopsy ・ H. Pylori fecal antigen ・ H. Pylori serology

Diseases The Helicobacter Foundation, 2005

Diseases- cont. Gastric and duodenal ulcers Gastric cancer ( 90%) Non-ulcer dyspepsia Weird syndromes

Treatment Antidiarrheals – bistmuth Antibiotics - metronidazole, tetracycline, amoxicilin Proton pump inhibitors - omeprazole, lansoprazole H2 receptor blockers – ranitidine, famotidine

My survival strategies D. S. Merrel et al, 2004

My virulence factors D. M. Monack et al, 2004

Details D. M. Monack et al, 2004

And now…finally the paper Activated macrophages produce NO using L-arginine as a substrate H. Pylori arginase competes with NOS2 for the substrate H. Pylori converts the substrate to urea and L-ornithine, not NO rocF gene encodes arginase Mutations in rocF gene helps the NO to kill H. Pylori

Experiment # 1A Hypothesis - the activated macrophage production of NO is inhibited by wt H. Pylori at physiologic L-arginine concentrations

Experiment #1A – cont. Conclusion: -only the wt H. Pylori inhibited NO released - the arginase deficient H. Pylori did not inhibit

Experiment # 1B Conclusion: adding more substrate will stop the competitive inhibition between H. pylori and activated macrophages

Experiment # 2 Hypothesis – H. Pylori wt compete for the same substrate with activated macrophages. This substrate is L-arginine.

Experiment # 2 –cont. Conclusion -the wt H. Pylori uses L-arginine decreasing the macrophage NO production because of the loss of the substrate - the rocF mutant does not use the L-arginine

Experiment # 3 Hypothesis – the macrophage production of NO is regulated by the H. Pylori arginase independently of iNOS expression Conclusion- both H. Pylori induce iNOS mRNA expression

Experiment # 4 Hypothesis – The bacterial arginase inhibits the release of NO by preformed iNOS in macrophages.

Experiment # 4-cont Conclusion: the wt H. Pylori inhibits macrophage NO production by the preactivated cells

Experiment # 5 Hypothesis – Only viable H.pylori can inhibit the release of macrophage NO Conclusion : only live H. Pylori can consume the substrate in order to inhibit the iNOS

Experiment # 6 Hypothesis – Inhibition of the host cell NO production is a survival strategy for H. Pylori. Conclusion – the wt H. Pylori has an increased rate of survival in comparison with rocF mutant H. Pylori in the presence of macrophages.

Experiment # 6 A

Experiment # 6B Conclusion: The rocF mutant H. Pylori survives in the presence of iNOS -/- macrophages.

Summary Bacterial arginase evolutionary adaptation survival strategy for H. pylori gastric mucosa protection

Don’t let your kids kiss us! The Helicobacter Foundation, 2005

Invitation

That is all I had to say… The End!